Our findings reveal that saxagliptin and other incretin-based drugs are associated with higher recovery rates from coma in patients with diabetes compared to other diabetes medications and that coma recovery rates are significantly higher among brain-injured patients with diabetes on incretin-based drugs than among patients without diabetes or patients treated with amantadine. This evidence concerns the gene GCG and diabetes mellitus.